Shield Therapeutics plc (STX) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.303x

Based on the latest financial reports, Shield Therapeutics plc (STX) has a cash flow conversion efficiency ratio of 0.303x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-4.49 Million ≈ $-546.85 USD) by net assets (GBX-14.86 Million ≈ $-1.81K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Shield Therapeutics plc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Shield Therapeutics plc - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Shield Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Shield Therapeutics plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Shield Therapeutics plc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Magnum Goldcorp Inc V:MGI	0.167x
Maven Income And Growth Vct Plc LSE:MIG1	-0.003x
Gateley (Holdings) Plc LSE:GTLY	0.129x
Ovoca Gold PLC IR:OVXA	-0.136x
Profusa, Inc. Common Stock NASDAQ:PFSA	0.091x
Carr's Group plc LSE:CARR	0.075x
IMMUTABLE HOLDINGS INC. F:B8X0	-0.142x
MAPSPEOPLE A/S DK-02 F:70R	N/A

Annual Cash Flow Conversion Efficiency for Shield Therapeutics plc (2014–2024)

The table below shows the annual cash flow conversion efficiency of Shield Therapeutics plc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Shield Therapeutics plc.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	GBX-1.05 Million ≈ $-127.95	GBX-7.01 Million ≈ $-852.49	6.663x	+500.42%
2023-12-31	GBX22.31 Million ≈ $2.71K	GBX-37.13 Million ≈ $-4.52K	-1.664x	+50.51%
2022-12-31	GBX5.43 Million ≈ $660.31	GBX-18.25 Million ≈ $-2.22K	-3.362x	-724.25%
2021-12-31	GBX41.03 Million ≈ $4.99K	GBX-16.74 Million ≈ $-2.04K	-0.408x	-782.15%
2020-12-31	GBX30.28 Million ≈ $3.68K	GBX-1.40 Million ≈ $-170.34	-0.046x	+63.44%
2019-12-31	GBX32.15 Million ≈ $3.91K	GBX-4.07 Million ≈ $-494.71	-0.126x	-2773.01%
2018-12-31	GBX40.43 Million ≈ $4.92K	GBX-178.00K ≈ $-21.66	-0.004x	+98.88%
2017-12-31	GBX41.21 Million ≈ $5.01K	GBX-16.15 Million ≈ $-1.97K	-0.392x	-84.95%
2016-12-31	GBX48.40 Million ≈ $5.89K	GBX-10.26 Million ≈ $-1.25K	-0.212x	-194.45%
2015-12-31	GBX-18.64 Million ≈ $-2.27K	GBX-4.18 Million ≈ $-508.95	0.224x	+22.79%
2014-12-31	GBX-18.28 Million ≈ $-2.22K	GBX-3.34 Million ≈ $-406.50	0.183x	--

About Shield Therapeutics plc

LSE:STX UK Drug Manufacturers - Specialty & Generic

Market Cap

$844.64K

GBX6.94 Billion GBX

Market Cap Rank

#30597 Global

#836 in UK

Share Price

GBX6.50

Change (1 day)

+1.56%

52-Week Range

GBX2.45 - GBX12.20

All Time High

GBX185.02